Lyka Labs Ltd
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
- Market Cap ₹ 510 Cr.
- Current Price ₹ 143
- High / Low ₹ 173 / 97.9
- Stock P/E 161
- Book Value ₹ 27.7
- Dividend Yield 0.00 %
- ROCE 3.95 %
- ROE -6.61 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 9.45% over past five years.
- Debtor days have increased from 67.4 to 88.6 days.
- Working capital days have increased from 36.9 days to 70.7 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 15m | Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127 | 119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 132 | |
99 | 111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 114 | |
Operating Profit | 28 | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 |
OPM % | 22% | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 13% |
3 | 25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 1 | |
Interest | 19 | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 4 |
Depreciation | 12 | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 9 |
Profit before tax | 0 | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 6 |
Tax % | 0% | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | |
-1 | -5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 3 | |
EPS in Rs | -0.33 | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 0.89 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 9% |
TTM: | 45% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 19% |
TTM: | 138% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 53% |
3 Years: | 0% |
1 Year: | 1% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 |
Reserves | 44 | 30 | 20 | 22 | 16 | 21 | 14 | -43 | -54 | -15 | -3 | 26 | 63 |
127 | 164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 35 | |
96 | 113 | 101 | 77 | 88 | 68 | 77 | 73 | 52 | 42 | 48 | 39 | 34 | |
Total Liabilities | 289 | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 168 |
93 | 162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 58 | |
CWIP | 47 | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 28 |
Investments | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
143 | 145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 83 | |
Total Assets | 289 | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 168 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | 89 | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | |
5 | -57 | 37 | 17 | -13 | -3 | -4 | -0 | -0 | -6 | 7 | -9 | |
-13 | -26 | -60 | -30 | -19 | -10 | -23 | 3 | -12 | -63 | -22 | 2 | |
Net Cash Flow | 3 | 6 | 4 | -1 | -0 | -3 | -1 | 9 | -3 | 10 | -5 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 211 | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 |
Inventory Days | 99 | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 |
Days Payable | 236 | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 |
Cash Conversion Cycle | 73 | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 |
Working Capital Days | 96 | -106 | -88 | -75 | -191 | -456 | -181 | -156 | -71 | 6 | 34 | 71 |
ROCE % | 10% | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov
-
Appointment of Company Secretary and Compliance Officer
12 Nov - Appointment of Mr. Shekhar R Singh as Company Secretary.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 Nov - Appointment of Mr. Shekhar R Singh as Company Secretary.
-
Statement Of Deviation Or Variation For The Quarter Ended 30Th September 2024 Of Funds Raised Through Preferential Issue Of Equity Share Warrants
Disclosure As per Regulation 32 Of The SEBI (LODR) Regulations, 2015 ( The SEBI Listing Regulations)
12 Nov - Statement of deviation for funds raised through preferential issue.
-
Intimation Under Regulations 30 And 33 Of The SEBI (LODR) Regulations, 2015 ( The SEBI Listing Regulations)
12 Nov - Board meeting outcome: financial results and appointments.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
-
Financial Year 2009
from bse
Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.